What is the population studied in the PROTECT trial?
The population studied in the PROTECT trial was adults aged 21 years or older with NYHA class II-IV chronic heart failure with reduced ejection fraction (LVEF ≤ 40%) who had experienced a destabilisation in their condition requiring hospital or clinic attendance for worsening heart failure symptoms.